The absence of satisfactory treatment options combined with the high risks for infants makes a compelling argument for aggressive protection against the disease in the U.S. through infant vaccination, along with the existing adolescent immunization strategy (to ensure continued immunity).
The phase 3 trial actually compared smoking cessation outcomes for vaccination and placebo for several months after the vaccination schedule, whereas the current study focused on the period just after immunization.